William Blair reissued their buy rating on shares of Pieris Pharmaceuticals (NASDAQ:PIRS) in a research report report published on Friday morning, AnalystRatings.com reports.
“Wenzel is considered a global expert in the treatment of asthma and has extensive experience in conducting clinical trials in asthma patients, having been a lead author on the Phase II trials of Dupixent (Wenzel et al., 2016) and a co-author in the Phase III pivotal trial. The call reaffirmed that FeNO is a well-validated clinical marker of biological activity in patients with asthma, and our belief that there is a significant market opportunity for PRS-060, an inhaled Anticalin targeting IL-4Rα.”,” William Blair’s analyst wrote.
A number of other analysts also recently issued reports on the company. Zacks Investment Research downgraded Pieris Pharmaceuticals from a hold rating to a sell rating in a research report on Tuesday, August 6th. ValuEngine upgraded Pieris Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Monday, July 29th. Cowen reiterated a buy rating on shares of Pieris Pharmaceuticals in a research report on Monday, May 13th. Robert W. Baird downgraded Pieris Pharmaceuticals from an outperform rating to a neutral rating and set a $5.00 price target for the company. in a research report on Tuesday, July 30th. Finally, HC Wainwright reiterated a buy rating and set a $7.00 price target on shares of Pieris Pharmaceuticals in a research report on Thursday, August 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $5.67.
Several institutional investors and hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC boosted its position in shares of Pieris Pharmaceuticals by 3.9% during the 2nd quarter. Renaissance Technologies LLC now owns 2,168,700 shares of the biotechnology company’s stock valued at $10,193,000 after acquiring an additional 80,900 shares during the last quarter. Nuveen Asset Management LLC bought a new stake in shares of Pieris Pharmaceuticals during the 2nd quarter valued at about $3,011,000. Wedge Capital Management L L P NC boosted its position in shares of Pieris Pharmaceuticals by 23.6% during the 1st quarter. Wedge Capital Management L L P NC now owns 525,324 shares of the biotechnology company’s stock valued at $1,760,000 after acquiring an additional 100,308 shares during the last quarter. Fosun International Ltd boosted its position in shares of Pieris Pharmaceuticals by 63.8% during the 2nd quarter. Fosun International Ltd now owns 364,693 shares of the biotechnology company’s stock valued at $1,616,000 after acquiring an additional 142,000 shares during the last quarter. Finally, Bank of America Corp DE boosted its position in shares of Pieris Pharmaceuticals by 793.1% during the 4th quarter. Bank of America Corp DE now owns 277,370 shares of the biotechnology company’s stock valued at $739,000 after acquiring an additional 246,312 shares during the last quarter. Hedge funds and other institutional investors own 56.15% of the company’s stock.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
Further Reading: How to read a candlestick chart
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.